| Identification | Back Directory | [Name]
2-(4-TERT-BUTYL-2,6-DIMETHYL-BENZYL)-4,5-DIHYDRO-1H-IMIDAZOLE | [CAS]
526-36-3 | [Synonyms]
Otrix
Otriven
Otrivin
Otrivine
Ba-11391
XYLOMETAZOLINE
Xylomethazoline
AKOS BBS-00000259
XYLOMETAZOLINEANDITSHYDROCHLORIDE
Xylometazoline (base and/or unspecified salts)
2-(4-tert-butyl-2,6-dimethylbenzyl)-2-imidazolin
2-(4-tert-Butyl-2,6-dimethylbenzyl)-2-imidazoline
2-Imidazoline, 2-(4-tert-butyl-2,6-dimethylbenzyl)-
ORGANIC CHEMICAL - XYLOMETAZOLINE HYDROCHLOROTHIAZIDE
Oxymetazoline Impurity 2（Oxymetazoline EP Impurity B）
2-(4-TERT-BUTYL-2,6-DIMETHYL-BENZYL)-4,5-DIHYDRO-1H-IMIDAZOLE
2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1H-imidazole
2-(4-TERT-BUTYL-2,6-DIMETHYL-BENZYL)-4,5-DIHYDRO-1H-IMIDAZOLE USP/EP/BP
1h-imidazole,2-((4-(1,1-dimethylethyl)-2,6-dimethylphenyl)methyl)-4,5-dihydr
2-[[4-(1,1-Dimethylethyl)-2,6-dimethylphenyl]methyl]-4,5-dihydro-1H-imidazole
1H-Imidazole,2-[[4-(1,1-dimethylethyl)-2,6-dimethylphenyl]methyl]-4,5-dihydro- | [EINECS(EC#)]
208-390-6 | [Molecular Formula]
C16H24N2 | [MDL Number]
MFCD00242956 | [MOL File]
526-36-3.mol | [Molecular Weight]
244.38 |
| Chemical Properties | Back Directory | [Melting point ]
131-133° | [Boiling point ]
394.2±21.0 °C(Predicted) | [density ]
1.00±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 49 mg/mL (200.51 mM);Ethanol: 49 mg/mL (200.51 mM) | [pka]
pKa 10.6±0.1(H2O
t = 22.0) (Uncertain) | [Water Solubility ]
Water: Insoluble | [CAS DataBase Reference]
526-36-3 |
| Hazard Information | Back Directory | [Uses]
Adrenergic (vasoconstrictor). | [Definition]
ChEBI: Xylometazoline is an alkylbenzene. | [Brand name]
Neo-Synephrine II (Sterling Winthrop); Otrivin
Hydrochloride (Ciba-Geigy). | [Synthesis]
Xylometazoline, 2-(4-tert-butyl-2,6-dimethylbenzyl)-2-imidazoline
(11.1.40), is also synthesized in a single reaction by cyclocondensation of 4-tert-butyl-2,6-
dimethylbenzylcyanide with ethylendiamine [43,44].
| [in vivo]
Xylometazoline (1 mg/mL, intranasal, single dose) improves sinusitis in rats[3].
Xylometazoline and its excipients, when used for prolonged periods, may cause ophthalmic problems such as dry eyes, corneal edema, cataracts, retinal nerve fiber layer damage, and vascular damage[4]. | Animal Model: | SpragueDawley rat induced by platelet-activating factor[3] | | Dosage: | 1 mg/mL; single dose | | Administration: | Intranasal administration | | Result: | Showed almost no vascular congestion, little infiltration, and the epithelium was completely intact. |
| [IC 50]
Alpha-1A adrenergic receptor: 0.05 μM (Ki); Alpha-1B adrenergic receptor: 0.30 μM (Ki); Alpha-1D adrenergic receptor: 0.15 μM (Ki); Alpha-2A adrenergic receptor: 0.88 μM (Ki); Alpha-2B adrenergic receptor: 1.7 μM (Ki); Alpha-2C adrenergic receptor: 0.19 μM (Ki) | [storage]
Store at -20°C |
|
|